- Published on:
Washington, Mar 17 (Prensa Latina) Syndax Pharmaceuticals, Inc. on Friday announced it found data from the Phase 1 portion of the ongoing Phase 1/2 AUGMENT-101 trial of revumenib in patients with nucleophosmin mutant (mNPM1) and KMT2A-rearranged (KMT2Ar) relapsed/refractory (R/R) acute leukemia.